Opdivo/Yervoy plus chemo hits in first-line NSCLC

Opdivo may be back in the running for first-line NSCLC after Bristol-Myers announced interim data from the Phase III CheckMate -9LA trial showed the triplet of Opdivo, Yervoy plus chemotherapy met its primary endpoint of overall survival vs. chemotherapy alone.

What remains an open question is how big the

Read the full 480 word article

User Sign In